BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 34486798)

  • 1. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release.
    Chan M; Vijay S; McNevin J; McElrath MJ; Holland EC; Gujral TS
    Mol Syst Biol; 2021 Sep; 17(9):e10426. PubMed ID: 34486798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
    Stebbing J; Sánchez Nievas G; Falcone M; Youhanna S; Richardson P; Ottaviani S; Shen JX; Sommerauer C; Tiseo G; Ghiadoni L; Virdis A; Monzani F; Rizos LR; Forfori F; Avendaño Céspedes A; De Marco S; Carrozzi L; Lena F; Sánchez-Jurado PM; Lacerenza LG; Cesira N; Caldevilla Bernardo D; Perrella A; Niccoli L; Méndez LS; Matarrese D; Goletti D; Tan YJ; Monteil V; Dranitsaris G; Cantini F; Farcomeni A; Dutta S; Burley SK; Zhang H; Pistello M; Li W; Romero MM; Andrés Pretel F; Simón-Talero RS; García-Molina R; Kutter C; Felce JH; Nizami ZF; Miklosi AG; Penninger JM; Menichetti F; Mirazimi A; Abizanda P; Lauschke VM
    Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33187978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
    Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
    Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
    EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.
    Pantazi I; Al-Qahtani AA; Alhamlan FS; Alothaid H; Matou-Nasri S; Sourvinos G; Vergadi E; Tsatsanis C
    Front Immunol; 2021; 12():683800. PubMed ID: 34248968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
    Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF
    Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib set to join the Covid-19 therapeutic arsenal?
    Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F
    Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
    Fauster A; Rebsamen M; Huber KV; Bigenzahn JW; Stukalov A; Lardeau CH; Scorzoni S; Bruckner M; Gridling M; Parapatics K; Colinge J; Bennett KL; Kubicek S; Krautwald S; Linkermann A; Superti-Furga G
    Cell Death Dis; 2015 May; 6(5):e1767. PubMed ID: 25996294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
    Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
    Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib: From Rheumatoid Arthritis to COVID-19.
    Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
    J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.
    Nystrom SE; Li G; Datta S; Soldano KL; Silas D; Weins A; Hall G; Thomas DB; Olabisi OA
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35472001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization.
    Wang X; Chen J; Shen Y; Zhang H; Xu Y; Zhang J; Cheng L
    Cytokine; 2024 Jul; 179():156620. PubMed ID: 38701735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release in human peripheral blood mononuclear cells.
    Chan M; Holland EC; Gujral TS
    EMBO Mol Med; 2022 Jun; 14(6):e15919. PubMed ID: 35579119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.
    Pirolli D; Righino B; De Rosa MC
    Mol Inform; 2021 Jun; 40(6):e2060080. PubMed ID: 33904240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
    Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
    Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
    Rommasi F; Nasiri MJ; Mirsaeidi M
    Mol Cell Biochem; 2022 Mar; 477(3):711-726. PubMed ID: 35013850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
    Akbarzadeh-Khiavi M; Torabi M; Rahbarnia L; Safary A
    Infection; 2022 Apr; 50(2):295-308. PubMed ID: 34902115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.